

April 21, 2014



## **Actinium to Present at RedChip Global Online CEO Conference April 24**

*CEO To Provide Insight Into Company's Progress and Business Strategy*

NEW YORK-- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will participate in RedChip's Global Online CEO Conference on Thursday, April 24, 2014.

Dr. Kaushik J. Dave, President and CEO of Actinium, will be reviewing the Company's clinical development and strategy in his presentation that will be held at 12:30 PM ET that day. The presentation will be followed by a live questions and answers session open to investors and other interested parties.

A live webcast of the presentation will be available at <http://www.redchip.com> and on the "Investor Relations" page of the Actinium website, [www.actiniumpharmaceuticals.com](http://www.actiniumpharmaceuticals.com). A replay of the webcast will also be archived on Actinium's website for 90 days following the presentation.

### **About Actinium Pharmaceuticals**

Actinium Pharmaceuticals, Inc. ([www.actiniumpharmaceuticals.com](http://www.actiniumpharmaceuticals.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical lomab<sup>TM</sup>-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of lomab<sup>TM</sup>-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

### **Forward-Looking Statement for Actinium Pharmaceuticals, Inc.**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial

performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Actinium Pharmaceuticals, Inc.

Investor/Media Relations:

Corey Sohmer, 646-459-4201

[csohmer@actiniumpharmaceuticals.com](mailto:csohmer@actiniumpharmaceuticals.com)

Source: Actinium Pharmaceuticals, Inc.